Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | platelet-activating factor receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus granulosus | g-protein coupled receptor | platelet-activating factor receptor | 342 aa | 302 aa | 22.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | Serine/threonine-protein kinase NEK16, putative | 0.0821 | 0.1779 | 1 |
Loa Loa (eye worm) | matrixin family protein | 0.0374 | 0.0695 | 0.6533 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.4217 | 1 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 3, putative | 0.16 | 0.3664 | 0.2293 |
Toxoplasma gondii | cathepsin CPC2 | 0.16 | 0.3664 | 0.2293 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.4217 | 1 | 1 |
Trypanosoma brucei | Serine/threonine-protein kinase NEK11, putative | 0.0821 | 0.1779 | 0.5 |
Brugia malayi | Matrix metalloprotease, N-terminal domain containing protein | 0.0205 | 0.0287 | 0.1169 |
Onchocerca volvulus | 0.0239 | 0.0369 | 0.2511 | |
Trypanosoma cruzi | Serine/threonine-protein kinase NEK11, putative | 0.0821 | 0.1779 | 1 |
Schistosoma mansoni | matrix metallopeptidase-7 (M10 family) | 0.0244 | 0.0381 | 0.0381 |
Echinococcus granulosus | serine:threonine protein kinase Nek1 | 0.0801 | 0.1729 | 1 |
Mycobacterium ulcerans | hydrolase | 0.0205 | 0.0287 | 0.5 |
Schistosoma mansoni | dipeptidyl-peptidase I (C01 family) | 0.4217 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0239 | 0.0369 | 0.0369 |
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.4217 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0821 | 0.1779 | 0.1779 |
Toxoplasma gondii | cathepsin CPC1 | 0.4217 | 1 | 1 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.4217 | 1 | 1 |
Trypanosoma cruzi | NIMA-related kinase, putative | 0.0821 | 0.1779 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0244 | 0.0381 | 0.2395 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.16 | 0.3664 | 0.2293 |
Plasmodium falciparum | dipeptidyl aminopeptidase 3 | 0.16 | 0.3664 | 0.2293 |
Onchocerca volvulus | Matrilysin homolog | 0.0449 | 0.0878 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.4217 | 1 | 1 |
Brugia malayi | Matrixin family protein | 0.0483 | 0.0959 | 1 |
Echinococcus multilocularis | serine:threonine protein kinase Nek1 | 0.0801 | 0.1729 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0205 | 0.0287 | 0.1169 |
Leishmania major | protein kinase, putative,serine/threonine-protein kinase Nek1, putative | 0.0821 | 0.1779 | 0.5 |
Brugia malayi | Hemopexin family protein | 0.0239 | 0.0369 | 0.2241 |
Mycobacterium tuberculosis | Probable peptidoglycan hydrolase | 0.0205 | 0.0287 | 0.5 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin B-like cysteine peptidase | 0.2617 | 0.6126 | 1 |
Mycobacterium leprae | PROBABLE HYDROLASE | 0.0205 | 0.0287 | 0.5 |
Trypanosoma brucei | Serine/threonine-protein kinase NEK16, putative | 0.0821 | 0.1779 | 0.5 |
Trypanosoma brucei | NIMA-related protein kinase | 0.0821 | 0.1779 | 0.5 |
Onchocerca volvulus | Matrix metalloproteinase homolog | 0.0374 | 0.0695 | 0.7317 |
Giardia lamblia | Encystation-specific protease | 0.16 | 0.3664 | 0.2293 |
Trypanosoma cruzi | Serine/threonine-protein kinase NEK11, putative | 0.0821 | 0.1779 | 1 |
Leishmania major | protein kinase, putative | 0.0821 | 0.1779 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0821 | 0.1779 | 0.5 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.16 | 0.3664 | 0.2293 |
Leishmania major | serine/threonine-protein kinase, putative | 0.0821 | 0.1779 | 0.5 |
Loa Loa (eye worm) | matrixin family protein | 0.0483 | 0.0959 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 34 mg kg-1 | In vivo for PAF antagonist activity in mice after oral administration | ChEMBL. | No reference |
F (ADMET) | = 30 % | Oral bioavailability in dog | ChEMBL. | No reference |
IC50 (functional) | = 7.5 nM | Inhibitory effect on PAF induced platelets aggregation in rabbit | ChEMBL. | No reference |
IC50 (functional) | = 7.5 nM | Inhibitory effect on PAF induced platelets aggregation in rabbit | ChEMBL. | No reference |
T1/2 (ADMET) | = 1.2 hr | Plasma half life of the compound was evaluated in Dog | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.